Arch Biopartners Announces Issuance of New U.S. Patent for Biofilm Inhibitor
TORONTO, ONTARIO--(Marketwire - July 14, 2011) - Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTC:FOIFF) today announced the U.S. Patent and Trademark Office has issued a method and composition patent for an invention preventing or inhibiting the growth of biofilm formation on biotic and abiotic surfaces.
This biofilm inhibitor was invented at the University of Colorado and the University of Alberta and was exclusively licensed to Arch.
Biofilm formation on abiotic surfaces is a particular concern in hospitals and to the medical implant industry. This invention presents a unique method of modifying solid surfaces to prevent certain biofilm formations, particularly those caused by Pseudomonas aeruginosa.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.